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ical stress with dobutamine. As per the institutional protocol, dobuta-
mine infusion was initiated at 10 μg/kg/min and the dose was
increased in increments of 10 μg/kg/min every 3 min. However, even
at a high dose of dobutamine (40 μg/kg/min), the patient was not
close to achieving her target heart rate. So she was given 0.25 mg of in-
travenous atropine. Soon after the injection, her target heart rate was
achieved (peak heart rate 168/min), with corresponding increase in
blood pressure (158/99mmHg). Immediately after achieving her target
heart, the dobutamine infusion was stopped. About 2 min after the
completion of image acquisition, the patient started complaining ofPharmacological stress testing using the combination of dobutamine
and atropine is a widely accepted standard diagnostic stress modality
for evaluating underlying coronary artery disease. This is used inmultiple
cardiac imaging modalities, including stress echocardiography, nuclear
perfusion imaging, and cardiac magnetic resonance imaging. Although
rare, occasional neuropsychiatric symptoms, including confusion and dis-
orientation have been reported following dobutamine–atropine stress
testing [1]. Transient global amnesia (TGA) is a syndrome characterized
by a sudden memory loss of recent and/or remote events with the tran-
sient inability to acquire new knowledge. We present a case of woman
who developed transient global amnesia after the completion of a dobu-
tamine–atropine stress echocardiogram.
A 54-year old woman with history of arthritis and remote history of
deep vein thrombosis was referred for an outpatient stress test for
evaluation of underlying ischemia. She was not on any medications,
including prescription or over the counter medication, and did not
report allergy to any medications. Her initial vital signs were stable
(baseline heart rate 68/min and blood pressure 106/68 mm Hg), while
her resting transthoracic echocardiogram was essentially normal with
normal left ventricularwall motion and ejection fractionwith trivial tri-
cuspid regurgitation. Of note, there was no identiﬁable patent foramen
ovale (PFO). Although initial attempt was made to perform an exercise
stress test, this was soon aborted as patient developedworsening of herpartment of Medicine, Mount
ork, NY, United States.
al).
land Ltd. This is an open access articlknee discomfort and the stress modality was changed to pharmacolog-
substernal heaviness and sensation of “heart racing”. In view of her
elevated heart rate and associated symptoms, initial Valsalva attempts
weremade followed by administration of 5mg of intravenousmetopro-
lol tartrate. Her symptoms resolved and her heart rate returned to
baseline after the administration of metoprolol. As per protocol she
was sent home soon after the test, but about 2 h after the completion
of test, she started complaining of intense headache and started repeat-
ing the same question over and over again, “Where am I?”. In view of
her persistent neurological symptoms she was emergently brought
back to the emergency room, where a thorough neurological check
and CT scan of the head without contrast was performed. Although
the patient was alert and oriented to time and person, her repetition
of the question, “where am I?” continued despite repeated reorienta-
tion. Her initial serum chemistries and CT scan of the head were within
normal limits. Shewas admitted to the hospital. By the followingmorn-
ing her symptoms had resolved and she had returned to her baseline.
Additional testing including MRI of the brain and MRA of the brain
and neck was unrevealing. However she was not able to recall any de-
tails around the time interval when she underwent the stress test.
Based on her clinical course, she was given the diagnosis of TGA. She
was discharged later that day and during serial follow-ups over the
next year did not have any recurrence of her neurological symptoms.
However, her amnesia for what happened around the stress test per-
sists to date.
While dobutamine atropine stress test is commonly performedwith
an excellent safety proﬁle, it is important for clinicians performing
dobutamine–atropine stress test to be aware of this rare but unnerving
side effect of TGA, which has not been reported often among literature
on cardiac stress testing [2]. TGA is a well-recognized and reported
phenomenon in neurological literature with incidence rates of 5.2
cases per 100,000 population, which increases among individuals whoe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[3]. However because of its dramatic onset and presentation, it can
cause extreme anxiety among both patients and health care providers.
TGA is a paroxysmal transient amnestic syndrome, whose prom-
inent feature is a loss of memory for recent events and an impaired
ability to retain new information.While most of the neurological exam-
ination is relatively unremarkable, the patients may appear anxious or
agitated, with or without loss of orientation to time or place. Repetitive
questioning about the transpiring event, as exhibited by our patient, is
another notable feature. During the episode patients are unable to cre-
ate newmemorieswhich cause profound anterograde amnesia. In addi-
tion variable duration of retrograde amnesia, varying from hours to
years, may also occur. These symptoms typically last less than 24 h. As
the syndrome improves, so does the associated amnesia, but since no
new memories are created during the syndrome, it is not uncommon
for patients to be left with permanent amnesia regarding the event [4].
The etiology behind TGA is still not clear, although a number of
hypotheses have been proposed. Some of the proposed hypotheses in-
clude, but are not limited to, cerebral arterial ischemia, venous conges-
tion, migraine, seizures, and psychological stressors. An interesting
hypothesis is related to the role of Valsalva maneuvers which causes
brief retrograde transmission of high venous pressure to the cerebral
venous system, especially in patients with underlying incompetent in-
ternal jugular valves [3,5,6]. As in our patient, Valsalva maneuvers are
often utilized to lower the heart rate after the peak heart rate has
been achieved during dobutamine cardiac stress testing. Hence this hy-
pothesismay be a potential explanation for the occurrence of TGA in our
patient.
A large study among 750 patients undergoing dobutamine stress
echocardiography which evaluated the occurrence of neuropsychiatric
symptoms within 24 h of the test, found that 7.1% of the patients
experienced some form of neuropsychiatric symptoms, while amnesia
was reported in only 0.4% of patients [1]. In the overall cohort, when
the atropine dose was N1.0 mg, the incidence rate of neuropsychiatric
symptoms increased up to 19.54%, while it also had the highest odds
ratio of being associated with neuropsychiatric symptoms. Although
our patient received atropine, it was a low dose of atropine (0.25 mg),
and her symptoms were different from those associated atropine use.In the same abovementioned study, atropine dose b1.0mg had a similar
incidence of neuropsychiatric symptoms as those patients in whom
atropine was not utilized for stress testing (2.78% vs. 3.83%, p-value =
0.5). In addition, atropine toxicity causes anti-cholinergic syndrome
whose features, may vary from central nervous systemdepression (som-
nolence or coma) to excitation (agitation, psychosis, and seizures) or a
combination of both,with associated dysarthria and ataxia [7]. This spec-
trum of clinical features is different from those associated with TGA, and
it is important to distinguish these two clinical conditions.
In conclusion, TGA is a rare side effect of dobutamine stress test,
which although rare and has a self-limited course with good overall
prognosis, because of its dramatic presentation requires differentiation
from other potential cerebral ischemic events. Increased awareness of
this syndrome can help early diagnosis of this syndrome and prevent
unnecessary invasive and noninvasive testing and alleviate patient
and health care providers' anxiety.Conﬂict of interest
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